Screener
Oruka Therapeutics, Inc. ORKA Compensation and benefits
Compensation and benefits at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(31,820) | $(20,999) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 6,968 | 4,883 |
| Net accretion of premiums and discounts on marketable securities | (446) | (1,797) |
| Non-cash lease expense | 143 | 62 |
| Depreciation expense | 43 | 16 |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Oruka Therapeutics, Inc.'s compensation and benefits?
- Oruka Therapeutics, Inc. (ORKA) reported compensation and benefits of $6.97M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s compensation and benefits changed year-over-year?
- Oruka Therapeutics, Inc.'s compensation and benefits increased by 42.7% year-over-year, from $4.88M to $6.97M.
- What does compensation and benefits mean?
- Total employee-related costs including salaries, wages, bonuses, commissions, stock-based compensation, health insurance, retirement contributions, and payroll taxes.
Ask your AI about Oruka Therapeutics, Inc.'s compensation and benefits.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude